1 Hour
Hyperkalemia management in Heart Failure
The Canadian Heart Failure Society invites you to join three world-renowned experts for an
in-depth look at the management of hyperkalemia in patients with heart failure. The experts
will be providing education on how hyperkalemia should be defined, as well as data and
best practices on treating hyperkalemia without discontinuing RAASi.
CHAIR
Justin Ezekowitz
MBBCh, MSc
Edmonton, AB
SPEAKERS
Shelley Zieroth
MD, FCCS, FHFSA (hon), FESC,
FACC, FHFA, FRCPC
Winnipeg, MB
Javed Butler
MBBS, MPH, MBA
Jackson, MS
LEARNING OBJECTIVES
• Understand the importance of optimal renin angiotensin aldosterone system inhibitor (RAASi) therapy dosing in the treatment of heart failure
• Recognize hyperkalemia as a barrier to optimal RAASi therapy and its impact on patient outcomes
• Understand the utility of novel potassium binders in optimizing the use of RAASi therapy, focus on the DIAMOND trial
